Literature DB >> 22777251

Late-stage Parkinson disease.

Miguel Coelho1, Joaquim J Ferreira.   

Abstract

The cardinal symptoms of Parkinson disease (PD) are asymmetrical bradykinesia, rigidity, resting tremor and postural instability. However, the presence and spectrum of, and disability caused by, nonmotor symptoms (NMS) are being increasingly recognized. NMS include dementia, psychosis, depression and apathy, and are a major source of disability in later stages of PD, in association with axial symptoms that are resistant to levodopa therapy. The model of clinical progression of PD should, therefore, incorporate NMS, instead of being restricted to motor signs and levodopa-induced motor complications. Patients with disabling motor complications are classified as having advanced PD, which has been thought to represent the ultimate stage of disease. However, deep brain stimulation to treat motor complications has dramatically changed this scenario, with implications for the definition of advanced-stage disease. As treatment improves and survival times increase, patients are increasingly progressing to a later phase of disease in which they are highly dependent on caregivers, and disability is dominated by motor symptoms and NMS that are resistant to levodopa. In this article, we review the changing landscape of the later stages of PD, and propose a definition of late-stage PD to designate patients who have progressed beyond the advanced stage.

Entities:  

Mesh:

Year:  2012        PMID: 22777251     DOI: 10.1038/nrneurol.2012.126

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  86 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  What predicts mortality in Parkinson disease?: a prospective population-based long-term study.

Authors:  E B Forsaa; J P Larsen; T Wentzel-Larsen; G Alves
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

3.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

4.  Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Authors:  Peter A Kempster; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

5.  Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations.

Authors:  Daniel Collerton; Elaine Perry; Ian McKeith
Journal:  Behav Brain Sci       Date:  2005-12       Impact factor: 12.579

6.  Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Authors:  M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

9.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

10.  Mortality from Parkinson's disease in England and Wales 1921-89.

Authors:  C E Clarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

View more
  64 in total

1.  RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.

Authors:  Elaine L Pranski; Nirjari V Dalal; Carson Van Sanford; Jeremy H Herskowitz; Marla Gearing; Carlos Lazo; Gary W Miller; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurobiol Dis       Date:  2013-01-11       Impact factor: 5.996

2.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

3.  NMR Metabolomics Analysis of Parkinson's Disease.

Authors:  Shulei Lei; Robert Powers
Journal:  Curr Metabolomics       Date:  2013

4.  Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.

Authors:  Priti Gros; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; R John Kimoff; Marta Kaminska
Journal:  Sleep Breath       Date:  2015-06-13       Impact factor: 2.816

5.  Disease stage dependency of motor and non-motor fluctuations in Parkinson's disease.

Authors:  Alexander Storch; Kristina Rosqvist; Georg Ebersbach; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2019-06-19       Impact factor: 3.575

Review 6.  Different diagnostic criteria for Parkinson disease: what are the pitfalls?

Authors:  Roongroj Bhidayasiri; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-15       Impact factor: 3.575

7.  Rotenone-induced energy stress decompensated in ventral mesocerebrum is associated with Parkinsonism progression in rats.

Authors:  Qunhua Bai; Junlin He; Yong Tang; Shibo Wang; Jingfu Qiu; Yang Wang; Chao Yu
Journal:  Exp Ther Med       Date:  2016-05-18       Impact factor: 2.447

8.  Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease.

Authors:  Doreen Gruber; Lisa Calmbach; Andrea A Kühn; Patricia Krause; Ute A Kopp; Gerd-Helge Schneider; Andreas Kupsch
Journal:  J Neural Transm (Vienna)       Date:  2019-01-25       Impact factor: 3.575

Review 9.  Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.

Authors:  Angelo Antonini; Bianca Nitu
Journal:  J Neural Transm (Vienna)       Date:  2018-07-13       Impact factor: 3.575

Review 10.  Treatment of advanced Parkinson's disease.

Authors:  Juan C Giugni; Michael S Okun
Journal:  Curr Opin Neurol       Date:  2014-08       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.